|Bid||33.00 x 800|
|Ask||165.00 x 800|
|Day's Range||37.93 - 38.86|
|52 Week Range||17.95 - 46.18|
|Beta (3Y Monthly)||1.80|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 8, 2018 - Aug 13, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||44.91|
SAN FRANCISCO, June 7, 2019 /PRNewswire/ -- Audentes Therapeutics, Inc. (BOLD), a leading AAV-based genetic medicines company focused on developing and commercializing innovative products for serious rare neuromuscular diseases, announced it has granted equity awards on June 5, 2019, that were previously approved by the Compensation Committee of its Board of Directors under the Audentes Therapeutics, Inc. 2018 Equity Inducement Plan, as a material inducement to employment to nine individuals hired by Audentes from April 25 through May 31, 2019. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4). The employees received, in the aggregate, options to purchase 22,800 shares of Audentes common stock. The options have an exercise price of $37.31 per share, which is equal to the closing price of Audentes common stock on June 5, 2019. One-fourth of the shares underlying each employee's option will vest on the one year anniversary of his or her date of hire and thereafter 1/48th of the shares underlying each employee's option will vest monthly, such that the shares underlying the option granted to each employee will be fully vested on the fourth anniversary of his or her date of hire, in each case, subject to each such employee's continued employment with Audentes on such vesting dates.
- Edward R. Conner, M.D. appointed as Senior Vice President and Chief Medical Officer - Fulvio Mavilio, Ph.D. promoted to Senior Vice President of Translational Science - Suyash Prasad, MBBS, MSc, MRCP, ...
SAN FRANCISCO , May 8, 2019 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a leading AAV-based genetic medicines company focused on developing and commercializing innovative products for serious ...
On a per-share basis, the San Francisco-based company said it had a loss of $1.13. The results missed Wall Street expectations. The average estimate of nine analysts surveyed by Zacks Investment Research ...
- Recently presented positive new data from ASPIRO, the Phase 1/2 study of AT132 for treatment of XLMTM - On track to submit updated ASPIRO data package with optimal dose selection to FDA in the second ...
Hedge fund managers like David Einhorn, Bill Ackman, or Carl Icahn became billionaires through reaping large profits for their investors, which is why piggybacking their stock picks may provide us with significant returns as well. Many hedge funds, like Paul Singer’s Elliott Management, are pretty secretive, but we can still get some insights by analyzing […]
- New data include 48 weeks of follow-up for six treated patients in dose Cohort 1 and 24 weeks for three treated patients in dose Cohort 2 - Significant and sustained improvements in neuromuscular function ...
SAN FRANCISCO , April 30, 2019 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a leading AAV-based genetic medicines company focused on developing and commercializing innovative products for ...
SAN FRANCISCO, April 23, 2019 /PRNewswire/ -- Audentes Therapeutics, Inc. (BOLD), a leading AAV-based genetic medicines company focused on developing and commercializing innovative products for serious rare neuromuscular diseases, today announced the launch of a new state-of-the-art, internal cGMP plasmid manufacturing facility in South San Francisco. Ensuring access to a reliable supply of high-quality plasmids is a critical aspect of gene therapy development.
Does the April share price for Audentes Therapeutics, Inc. (NASDAQ:BOLD) reflect what it's really worth? Today, we will estimate the stock's intrinsic value by projecting its future cash flows and then discounting them to today's v...
- Oral presentation of ASPIRO results to include new data, with up to 48-weeks of follow-up for all patients in dose Cohort 1 and up to 24-weeks in the earliest patients in dose Cohort 2 - Presentation ...
Gene therapy continues to be in focus given the recent spate of deals and acquisitions. We highlight four stocks, which have promising gene therapy candidates in their pipeline.
- Platform expansion combines the delivery power of AAV with the precision tools of antisense oligonucleotides to develop best-in-class treatments for Duchenne muscular dystrophy (DMD) and myotonic dystrophy ...
SAN FRANCISCO, April 1, 2019 /PRNewswire/ -- Audentes Therapeutics, Inc. (BOLD), a biotechnology company focused on developing and commercializing innovative gene therapy products for patients living with serious, life-threatening rare diseases, today announced that Mark A. Meltz, J.D. has joined the company as Senior Vice President, General Counsel and Sarah J. Spencer has joined the company as Vice President, Corporate Communications. In addition, Thomas P. Soloway, currently Senior Vice President, Chief Financial Officer, has been promoted to the newly created position of Executive Vice President, Chief Financial Officer. Tom will continue to lead the finance, accounting, and investor relations functions. Mark will lead the legal, compliance, and corporate governance functions. Sarah will be responsible for internal and external communications to build global awareness of the company, its mission, culture, and innovative product portfolio.
NEW YORK, March 29, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Spark Therapeutics is unlikely to get a better offer than Roche's $4.8 billion bid, an analyst says, suggesting instead a pair of other gene therapy names could garner buyout interest.
It is doubtless a positive to see that the Audentes Therapeutics, Inc. (NASDAQ:BOLD) share price has gained some 39% in the last three months. But in truth the last yearRead More...
Audentes Therapeutics (BOLD) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.